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The aim of this study is to characterize the relation-ship between major depression and the metabolic
syndrome in a large community based sample of
Australian men and women aged 26–90 years. A life-
time history of major depression was assessed by
telephone interview following the DSM–III-R. A
current history of metabolic syndrome was assessed
following the United States National Cholesterol
Education Program Adult Treatment Panel III (NCEP
AP-III) guidelines 1 to 3 years later. Logistic regres-
sion was used to estimate the association between
depression and the metabolic syndrome, and its com-
ponent criteria, controlling for age, sex and alcohol
dependence. There was no association between a
lifetime history of major depression and the presence
of the metabolic syndrome. There was a weak asso-
ciation between depression and low high-density
lipoprotein cholesterol but not with other component
criteria of the metabolic syndrome. Despite calls for
interventions directed at depression to reduce the
onset of the metabolic syndrome there are important
failures to replicate in large samples such as this, no
consensus regarding the threshold at which depres-
sion may pose a significant risk even allowing for
heterogeneity across populations, and no consensus
regarding confounders that may explain inter-study
differences. The absence of any dosage effect of
depression on the associated risk for the metabolic
syndrome in other unselected samples does not
support a direct causal relationship. The call for inter-
vention studies on the basis of the currently
published evidence base is unwarranted.
Keywords: depressive disorder, major; metabolic syn-
drome; cardiovascular diseases
The metabolic syndrome is defined by a combination
of central obesity, high blood pressure, low high-
density lipoprotein (HDL) cholesterol, elevated
triglycerides and hyperglycemia. These clustered risk
factors have been associated with the development of
type 2 diabetes and cardiovascular disease (Reaven,
1988). Identifying factors associated with the develop-
ment of the metabolic syndrome is therefore of
considerable public health interest. Depression may be
one such factor. Depression is associated with an
increased risk for diabetes and cardiovascular disease
(Glassman, 2008) but the mechanisms underlying this
association are still poorly understood. The metabolic
syndrome may partly mediate the association. The
relationship between depression and the metabolic
syndrome has been examined by at least 18 studies
(Table 1). A significant association has been reported
for 14 samples but whether this reflects an important
causal relationship or the impact of confounding or
mediating variables is unclear.
A history of major depression is associated with an
approximately twofold increased risk of the metabolic
syndrome in community and population based
samples (Goldbacher et al., 2009; Roriz-Cruz et al.,
2007; Kinder et al., 2004). Depression defined by a
clinically meaningful threshold applied to subject-
rated symptoms is also associated with an
approximately twofold increased risk of the metabolic
syndrome (Skilton et al., 2007; Takeuchi et al., 2009;
Vanhalla et al., 2009). Subject-rated checklists survey
recent symptoms of depression and the similarity of
the estimated association with the metabolic syn-
drome using either a lifetime history or recent
symptoms of depression may indicate that the timing
of depression is less important than ever meeting a
clinically relevant threshold. An association between
the metabolic syndrome and depression is not,
however, confined to a clinically significant level of
depression symptoms. Mean differences in the level
and severity of subject rated depression symptoms
between those with and without the metabolic syn-
drome are typically small and well within the normal
range (Dunbar et al., 2008; Hildrum et al., 2009;
Skilton et al., 2007; Takeuchi et al., 2009; Vogelzangs
et al. 2007a; 2007b).
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Multiple episodes of depression are not associated
with a greater risk for metabolic syndrome than single
episodes of depression (Goldbacher et al., 2009; Kinder
et al., 2004) and duration of depression does not
predict future metabolic syndrome (Heiskanen et al.,
2006). There is no evidence at all for a dosage effect of
depression on risk for the metabolic syndrome except in
clinical samples with diagnosed cardiovascular disease
(Vaccarino et al., 2008) or related risk factors (Skilton
et al., 2007). The population-based Norwegian HUNT
study found a very weak association between depres-
sion and the metabolic syndrome was unaffected by the
inclusion or exclusion of those with cardiovascular
disease (Hildrum et al., 2009). An apparent dosage
effect of depression on risk for the metabolic syndrome
in the presence of cardiovascular risk factors in clinical
samples may therefore reflect chance findings or ascer-
tainment bias. Findings regarding the effect of temporal
order on the estimated association between depression
and the metabolic syndrome are inconsistent. Metabolic
syndrome in adulthood did not predict the future onset
of depression (Goldbacher et al., 2009; Räikkönen et
al., 2002) but the metabolic syndrome in childhood
predicted higher levels of depression symptoms in
adulthood (Pulkki-Råback et al., 2009).
There are more reports of a positive association
between depression and the metabolic syndrome in
women than men (Table 1) and the possible impor-
tance of gender as a moderating variable is regularly
raised. The prevalence of depression is also higher in
women than men (Kessler, 2003) and there may conse-
quently be a sex difference in power to detect an
association. In the largest studies conducted to date
there is no evidence that sex moderates the association
between depression and the metabolic syndrome
(Hildrum et al., 2009; Kinder et al., 2004).
Analysis of the individual criteria that comprise
the metabolic syndrome, which may yield insights
into the basis for any observed association with
depression, has generated less consistent findings
than analysis of the composite measure. Positive
associations are most often reported between depres-
sion and central obesity/body mass index (Dunbar et
al., 2008; Herva et al., 2006; McCaffery et al., 2003;
Pulkki-Råback et al., 2009; Takeuchi et al., 2009;
Vaccarino et al., 2007) or HDL cholesterol (Dunbar
et al., 2008; Igna et al., 2008; Vanhala et al., 2009;
Vogelzangs et al., 2007a) and triglycerides (Kinder et
al., 2004; McCaffery et al., 2003; Pulkki-Råback et
al., 2009; Vaccarino et al., 2007). Depression is
therefore more often associated with the construct of
metabolic syndrome than with its component parts
(Vogelzangs et al., 2007b). Power to detect an associ-
ation with individual criteria should be greater than
power to detect an association with a (less prevalent)
cluster of the same criteria unless it is the combina-
tion of the unique variance each criteria index that
largely drives the association. It may be the variance
indexed by the clustering of metabolic criteria that
matters (e.g., elevated blood pressure plus abnormal
HDL cholesterol plus elevated triglycerides rather
than elevated blood pressure alone). A significant
association between major depression and the meta-
bolic syndrome is still statistically significant after
adjustment for each of the individual metabolic syn-
drome criteria (Roriz-Cruz et al., 2007).
The aim of this report is to characterize the rela-
tionship between the clinical syndrome of major
depression and the metabolic syndrome in a large
community-based sample of Australian men and
women aged 26 to 90 years.
Methods
Subjects
Subjects were ascertained in 1992-1993 from the vol-
unteer Australian Twin Registry for a study of
substance abuse and common psychiatric disorders.
Psychiatric history was surveyed by telephone using
the Semi-Structured Assessment for the Genetics of
Alcoholism, adapted for the Australian population
(SSAGA-Oz). A detailed account of the ascertainment
of twins for this study is provided in Heath et al.
(1997). Between 1993 and 1996 participants in the
SSAGA-Oz study were invited to participate in a
second study involving donation of a blood sample
and measurement of physical characteristics. This is
known as the SSAGA-Blood Study (Hansell et al.,
2008; Whitfield et al., 1998). One of the main objec-
tives of the blood study was to collect DNA and
individuals were targeted for recruitment primarily if
they were a dizygotic twin who had not previously
donated blood (Hansell et al., 2008).
The SSAGA-Oz study comprised 5,996 individuals,
4,044 of whom were approached to participate in the
SSAGA-Blood Study. Of these 3,389 (84%) partici-
pated; 3,375 provided blood samples and non-invasive
physical measures, the remaining 14 provided only
physical measures. The SSAGA-Blood Study comprised
2,248 women and 1,141 men and these individuals are
the subject of the present report. The sample com-
prised 534 female–female monozygotic (MZ) pairs and
133 female MZ twins from unmatched pairs, 204
male–male MZ pairs and 93 male MZ twins from
unmatched pairs, 283 female–female dizygotic (DZ)
pairs and 106 female DZ twins from unmatched pairs,
110 male–male DZ pairs and 66 male DZ twins from
unmatched pairs, and 282 opposite sex DZ pairs and
165 individual twins from an unmatched pair. The
average age of female subjects was 45 years (range 26–
90 years). The average age of male subjects was 44
years (range 30–85 years).
The SSAGA-Oz study and the SSAGA-Blood study
were both approved by the institutional research and
ethics committees and all subjects participating in each
study gave informed consent.
Measures
The SSAGA interview was administered by telephone
during 1993–1994 and included an assessment of the
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subject’s history of major depression. Psychiatric assess-
ments were conducted by a team of 20 trained
interviewers. All interviews were audio-taped for quality
control unless the subject refused permission. Separate
interviewers assessed each member of a twin pair. A life-
time history of DSM-IV major depression was assigned
from the SSAGA-Oz interview data by computer algo-
rithm (Bierut et al., 1999; Heath et al., 1997).
The metabolic syndrome was assessed in person
during 1993-1996 and after the SSAGA interview.
Systolic and diastolic blood pressures were measured
when blood was collected using an automated blood
pressure recorder (Dynamap 845 Vital Signs Monitor;
Critikon Inc.) with subjects seated. The mean of two
results taken at 1-min intervals was used. Body mass
index was calculated from self-reported height and
weight. Subjects also completed a questionnaire that
included information on current and past medical
conditions and listed all medications they were cur-
rently taking.
Serum was separated from blood and stored at
–70°C until analysis. Total cholesterol, glucose and
triglycerides were measured by Boehringer Mannheim
methods on a Hitachi 747 analyzer. HDL was measured
by precipitation of non-HDL with dextran/MgSO4
 followed by enzymatic cholesterol assay. Samples were
not collected in a fasting state, but information on time
of last meal/snack and type of food eaten was collected.
The United States National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP-III,
2001) defines the metabolic syndrome as the presence
of at least three of the following five criteria:
1. Abdominal obesity: Waist circumference ≥ 102 cm
for men, ≥ 88 cm for women.
2. Fasting triglycerides: ≥ 150 mg/dL (1.7 mmol/L) or
relevant drug treatment.
3. HDL: < 40 mg/dL (0.9 mmol/L) for men, < 50
mg/dL (1.1 mmol/L) for women.
4. Blood pressure: systolic blood pressure ≥ 130
mmHg and/or diastolic ≥ 85 mmHg or antihyper-
tensive medication.
5. Fasting glucose: ≥ 100 mg/dL (5.6 mmol/L) or
insulin/hypoglycemic medication. 
The SSAGA-Blood study did not measure waist
 circumference but did measure body mass index
(BMI). Waist circumference and BMI are highly corre-
lated (Bigaard et al., 2003) and obesity (BMI >
30kg/m2) was therefore used to define NCEP ATP-III
criterion 1 rather than abdominal obesity.
Assays for plasma triglycerides and glucose are
affected by recent food ingestion and medication can
correct elevated blood pressure, glucose or lipids. The
guidelines of Meyer et al. (2008) are therefore used for
non-fasting samples and for subject’s using relevant
medication:
1. The NCEP ATP-III glucose criterion is considered
met if subjects were (a) on prescribed hypo-
glycemic medications (b) using insulin or (c) had
random glucose greater than or equal to 200
mg/dL (11.1 mmol/L).
2. The NCEP ATP-III glucose criterion is considered
not met if the non-fasting measure is less than 100
mg/dL (5.6 mmol/L).
3. A nonfasting glucose between 100–199 mg/dL
(5.6–11 mmol/L) is treated as missing.
4. The NCEP ATP-III triglyceride criterion is consid-
ered not met if the random serum value is less than
150 mg/dL (1.7 mmol/L).
5. A nonfasting triglyceride value of 150 mg/dL (1.7
mmol/L) or more is treated as missing.
6. The NCEP ATP-III blood pressure criterion is con-
sidered met if the value is above the cut-off or the
subject is taking anti-hypertensive medication.
7. The NCEP ATP-III HDL cholesterol criterion is
considered met if the value is below the cut-off.
8. The triglyceride criterion is considered met if the
subject is taking relevant medication.
Subjects were deemed to be taking relevant medication
if they recorded the name of the relevant medication
they were using on the survey questionnaire. Those
who reported having diabetes were considered to have
met the criterion for elevated glucose.
Information on time between sample collection
and last meal was available for 3,049 participants.
The mean number of hours between food intake and
sample collection was 3.9, with a range of less than 1
hour to 24 hours. The time elapsed between last meal
and sample collection was eight hours or greater for
412 (14%) of participants.
Subjects met criteria for the metabolic syndrome if
they met any three of the modified NCEP ATP-III criteria.
Statistical Methods
Logistic regression is used to evaluate participation
bias. The dependent variable is participation in the
SSAGA-OZ Blood study by participants in the larger
SSAGA-Oz study. Logistic regression is used to evalu-
ate bias associated with missing data. The dependent
variable is missing data for the estimation of the meta-
bolic syndrome amongst participants in the
SSAGA-Blood study. The representativeness of the
SSAGA-Blood study sample is estimated by conduct-
ing a comparison with the AusDiab study (Cameron et
al., 2008). AusDiab ascertained a representative
sample of 11,247 non-institutionalized Australians
over the age of 24. Multiple logistic regression is used
to test if a lifetime history of major depression is asso-
ciated with the presence of the metabolic syndrome,
adjusting for the subject’s age, sex, and level of alcohol
dependence which was a focus of the original SSAGA-
Oz study. The dependent variable is the metabolic
syndrome. In the absence of an observed association
between major depression and the metabolic syn-
drome within individuals, a conditional logistic
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regression will be used to confirm the absence of an
association within twin pairs because negative con-
founding due to familial effects could mask a within
family association. There were n = 224 twin pairs dis-
cordant for a lifetime history of major depression who
had non-missing metabolic data. Means and associated
95% confidence intervals are estimated for continuous
outcome measures and covariates. Proportions are esti-
mated for categorical variables. Odds ratios are used to
summarize the estimated association between lifetime
history of major depression and the presence of the
metabolic syndrome, and between lifetime history of
major depression and each of the component criteria of
metabolic syndrome. Data from twin pairs is not statis-
tically independent. Standard errors are therefore
calculated using robust estimators of variance
(Williams, 2000). These analyses were conducted using
Stata 10.1 for Macintosh (Stata Corporation, 2008).
Results
Participation Bias
Participation in the SSAGA-OZ Blood study is not pre-
dicted by age (p = 0.67) or history of major depression
(p = 0.31) or alcohol dependence (p = 0.79). Males
were less likely to participate than females (O.R. =
0.80, 95% C.I. = 0.65 – 1.00, p = 0.05). Age (p = 0.56),
history of major depression (p = 0.99) or alcohol
dependence (p = 0.97) and gender (p = 0.09) do not
differ significantly between participants in the SSAGA-
OZ Blood Study and the full SSAGA-OZ sample.
Bias Associated With the Pattern of Missing Data
The criteria for the metabolic syndrome could be esti-
mated for 2,525 participants (75%) of the SSAGA-OZ
Blood study. Complete metabolic data was not
obtained for all individuals (Table 2) and some data are
not missing at random. Women are less likely to have
missing data for blood pressure (O.R. = 0.79, 95% C.I.
= 0.66–0.94, p < .01) or serum glucose than men (O.R.
= 0.75, 95% C.I. = 0.62–0.92, p < .01). Women are
more likely to be missing HDL cholesterol data then
men (O.R. = 1.57, 95% C.I. = 1.10–2.26, cholesterol p
= .01). Gender did not predict missing height or weight.
Age did not predict missing data for any variable.
Neither major depression nor alcohol dependence pre-
dicted any missing metabolic data.
Comparability With a Nationally Representative Sample
The prevalence of the metabolic syndrome was lower
in SSAGA-OZ Blood study (6%) than in the AusDiab
study (15–30% depending upon definition used;
Table 3). In all other respects participants in the
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Table 2
Prevalence of a Lifetime History of Major Depression and the Metabolic Syndrome
Measure Female Male Total
% No. % No. % No.
Lifetime history of major depression
No 77.4 1740 84.2 961 79.7 2701
Yes 22.6 508 15.8 180 20.3 688
Missing 0 0 0
Metabolic syndrome
No 94.3 1638 94.2 742 94.3 2380
Yes 5.7 99 5.8 46 5.7 145
Missing 511 353 864
Obese
No 84.8 1879 88.5 993 86.1 2872
Yes 15.2 336 11.5 129 13.9 465
Missing 33 19 52
High blood pressure
No 55.7 648 39.4 258 49.8 906 
Yes 44.3 515 60.6 397 50.2 912
Missing 1085 486 1571
Low HDL cholesterol
No 88.2 1896 87.8 932 88.1 2828
Yes 11.8 254 12.2 129 11.9 383
Missing 98 80 178
High triglycerides
No 95.0 1503 86.3 503 92.7 2006
Yes 5.0 79 13.7 80 7.3 159
Missing 666 558 1224
Elevated glucose
No 65.2 1271 70.0 671 66.8 1942
Yes 34.8 679 30.0 287 33.2 966
Missing 298 183 481
SSAGA-OZ Blood study are broadly comparable to
those in the AusDiab study.
Relationship Between the Metabolic Syndrome and Depression
There are no significant differences in the metabolic
outcomes of individuals with or without a history of
major depression (Table 4). The association between a
lifetime history of major depression and the metabolic
syndrome is not significant (Table 5). There is no main
effect of gender on risk for the metabolic syndrome
(p = .59) in a multiple regression model controlling
for history of major depression (p = .45) but risk did
increase with age (OR = 1.04 for age coded in years,
95% CI = 1.03–1.05, p < .001). There is a weak asso-
ciation between low HDL and a history of major
depression (Table 5). The associations between all
other individual criteria for the metabolic syndrome
and a history of depression are small and nonsignifi-
cant (Table 5).
A conditional logistic regression confirmed the
absence of an association between depression and the
metabolic syndrome within twin pairs, adjusting for
sex and zygosity. Considering only MZ pairs discor-
dant for a history of major depression where the
dependent variable was the metabolic syndrome and
the independent variable was major depression (sex
was not included as MZ twins are always the same
sex), the association between the metabolic syndrome
and depression was nonsignificant (OR = 1.33, 95%CI
= 0.46–3.84, P = .59). Considering only DZ pairs dis-
cordant for a history of major depression where the
dependent variable was the metabolic syndrome and
the independent variables were major depression and
sex, the association between the metabolic syndrome
and depression was also non-significant (OR = 1.17,
95%CI = 0.36–3.47, P =.78). The association with sex
was nonsignificant (p = .99). Combining MZ and DZ
twins in a single model, the interaction between zygos-
ity and major depression, and zygosity and major
depression and sex, and the main effect of sex were
all non-significant in association with the metabolic
syndrome. A reduced model including only major
depression as the dependent variable indicated no sig-
nificant association between depression and the
metabolic syndrome in this subsample of discordant
twins (OR = 0.94, 95%CI = 0.46–1.9, P = .86). There
is therefore no evidence of negative confounding due to
familial effects, and consequently no evidence of an
association between major depression and the meta-
bolic syndrome in this community sample.
Discussion
This is the first Australian study to examine the rela-
tionship between major depressive disorder and risk
for the metabolic syndrome, and in this sample there
was no association. This study ascertained a large
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Table 3
Comparability of the SSAGA-OZ Blood Study Sample With the Nationally Representative AusDiab Sample





























community based sample of men and women that
covered the entire adult age range, administered a clin-
ical interview to assess lifetime history of major
depression and assessed that lifetime history 1–3 years
before the assessment of the metabolic syndrome fol-
lowing international guidelines. One previous
Australian study reported a significant difference in
the mean level of subject-rated depression symptoms
among individuals with and without the metabolic
syndrome but in both groups mean depression scores
were well within the normal range (Dunbar et al.,
2008). When a clinically meaningful threshold was
used to define possible cases of depression the associa-
tion between depression and the metabolic syndrome
in that study was nonsignificant, consistent with our
own findings.
The study conducted by Dunbar and colleagues is
worth scrutinizing because like many other studies
they report significant but small group differences and
they surveyed a stratified random sample that is
unlikely to be biased. The 7-item HADS depression
subscale used to assess recent symptoms of depression
rates each symptom on a scale from 0-3 and the total
depression score may therefore range between 0 and
21, with higher scores reflecting higher levels of
depression. The normal range is defined as a score < 8.
The mean symptom rating among individuals with
and without the metabolic syndrome was 3.4 and 2.9
respectively. Individuals with and without the meta-
bolic syndrome therefore had depression scores that
were well within the normal range. Another study that
used the HADS depression subscale ascertained a
sample referred by a primary care physician to an out-
patient Centre for Prevention and Detection of
Atherosclerosis because of the presence of at least one
traditional cardiovascular risk factor (Skilton et al.,
2007). The mean HADS depression symptom rating in
those with and without the metabolic syndrome in
that study was 5.3 versus 4.4 in men and 6.5 versus
5.3 in women. Subjects without the metabolic syn-
drome in a non-random sample enriched for
cardiovascular risk factors therefore had a higher
mean HADS depression score than subjects with the
metabolic syndrome in a random stratified population
based sample. A HADS depression score alone clearly
cannot be used to determine who is at risk of develop-
ing the metabolic syndrome, and very small mean
differences that are well within the normal range
should not be over interpreted. In the only other study
we located that used the HADS depression subscale
the weak association between depression and the
metabolic syndrome was entirely confounded
(Hildrum et al., 2009).
Several studies have reported an association between
the metabolic syndrome and low levels of depression but
not with common covariates of depression such as
anxiety (e.g., Hildrum et al., 2009; Skilton et al., 2007;
Takeuchi et al., 2009; Vogelzangs et al., 2007b). This
apparent specificity may point away from an important
comorbidity with major depression and towards some-
thing only modestly correlated with it. If covariates
explain the association between depression and the
metabolic syndrome then variation in the presence or
prevalence of these covariates may account for inter-
study differences. In the largest population based study
conducted to date the authors reported a very weak
association between depression and the metabolic syn-
drome that was entirely confounded, mainly by physical
activity and education (Hildrum et al., 2009). It is there-
fore important to identify which factors reliably account
for an association between depression and the metabolic
syndrome because these factors may play an important
role in linking behavioral and physical health outcomes,
and, if evidence for a causality is demonstrated, they
may be a better target for intervention directed at the
metabolic syndrome than depression (cf. Dunbar et al.,
2008; Goldbacher et al., 2009).
There may be heterogeneity within the metabolic
syndrome and associated variation in outcome (Kahn,
2007). The syndrome requires at least three criteria to
be present but studies do not typically report the
pattern of criteria observed within their samples and
many studies, including our own, use slightly modified
criteria. Investigating associations with individual cri-
teria of the syndrome only partly addresses the issue if
it is the clustering of risk factors that is important. We
did, however, find a weak association between low
HDL cholesterol and a history of major depression,
355Twin Research and Human Genetics August 2010
Major Depression and the Metabolic Syndrome
Table 4
Characteristics of Subjects With and Without a Lifetime History of Depression
Lifetime history of depression No history of depression
Mean Range Mean Range
Body mass index (kg/m2) 25.3 13–44 25.2 15–49
Systolic blood pressure (mmHg) 126.2 92–186 127.7 86–109
Diastolic blood pressure (mmHg) 77.2 51–119 77.6 44–119
Serum HDL cholesterol (mmol/L) 1.4 0.6–3.0 1.4 0.6–3.5
Serum triglycerides (mmol/L) 1.8 0.4–9.2 1.7 0.3–19.3
Plasma glucose (mmol/L) 5.2 2.9–14.1 5.2 2.4–21.8
Metabolic syndrome 6% — 6% —
consistent with some (e.g., Dunbar et al., 2008; Maes
et al., 1997; Vanhala et al., 2009;) but not all (Brunner
et al., 2002) previous studies.
Understanding the relationship between depression
and risk for the metabolic syndrome is important
because a history of depression predicts future risk for
heart disease. Variables reported to mediate the
observed association between depression and the
metabolic syndrome include socio-economic and
lifestyle variables but these do not explain the
observed association in all samples. There may be
both direct and indirect pathways between depression
and the metabolic syndrome (Igna et al., 2008); HDL,
indices of socio-economic status and lifestyle factors
may all be important.
Despite calls for interventions directed at depres-
sion to reduce the onset of the metabolic syndrome
there are important failures to replicate in large
samples, no consensus regarding the threshold at
which depression may pose a significant risk and, cur-
rently, no consensus regarding confounders that
explain inter-study differences. The absence of any
dosage effect of depression on the associated risk for
the metabolic syndrome in other unselected samples
does not support a direct causal relationship. The call
for intervention studies on the basis of the currently
published evidence base is unwarranted.
Limitations
There are several limitations of the current study that
should be considered when interpreting the findings
presented here. First, the assessment of a lifetime
history of major depression was always conducted
before the assessment of the metabolic syndrome but
the time between assessments was no more than 3
years. In some cases, therefore, the time between an
episode of major depression and the assessment of the
metabolic syndrome was less than three years. Second,
the criteria used to define the metabolic syndrome
vary slightly from those recommended by the NCEP
ATP-III (2001). Third, participants in this study had a
lower prevalence of the metabolic syndrome than the
wider Australian community (Cameron et al., 2008),
consistent with a bias towards participation by physi-
cally healthier subjects. The prevalence of a lifetime
history of major depression in this sample is, however,
consistent with estimates from other community-based
samples, at around 20%, and if there had been an
important association with the metabolic syndrome
we should have observed it in this sample.
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